The Gene Messenger: Advancing Neurological Gene Therapy

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Gene Messenger: Advancing Neurological Gene Therapy



ReachMD Healthcare Image

Hear about groundbreaking advances in neurological gene therapy for patients with Parkinson’s disease.

  • In Partnership with

  • Overview

    For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery.

    © 2024 NewYork-Presbyterian

Schedule30 May 2024